Catalent Pharma Solutions, Inc. $350,000,000 7.875% Senior Notes Due 2018 REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • September 18th, 2012 • Catalent Pharma Solutions, Inc. • Pharmaceutical preparations • New York
Catalent Pharma Solutions, Inc., a Delaware corporation (the “Issuer”), proposes to issue and sell to the several initial purchasers named in Schedule A hereto (collectively, the “Initial Purchasers”), upon the terms set forth in a purchase agreement, dated as of September 5, 2012 (the “Purchase Agreement”), $350,000,000 aggregate principal amount of its 7.875% Senior Notes due 2018 (the “Initial Securities”) to be unconditionally guaranteed (the “Guarantees”) by each of the subsidiaries that are party to the Purchase Agreement (collectively, the “Guarantors” and, together with the Issuer, the “Company”). The Initial Securities will be issued pursuant to an indenture, to be dated as of September 18, 2012 (the “Indenture”), among the Issuer, the Guarantors and The Bank of New York Mellon, as trustee (the “Trustee”). As an inducement to the Initial Purchasers to purchase the Initial Securities, the Company agrees with the Initial Purchasers, for the benefit of the holders of the Initial
